Mycobacteria diseases are chronic in many regions of the world, with human TB being second only to Covid-19 as the most infectious fatal disease. These diseases are zoonotic (they can jump from animals to humans) with reservoirs of disease found in wild populations. Therefore, effective methods of detection are urgently required.
Actiphage is unique as it is able to detect and identify live mycobacteria at a very early stage of infection, unlike other tests which rely on an immune response.
For human TB, clinical trials are in progress to assess the use of Actiphage as an improved diagnostic, particularly for children. Early findings have been published in the peer-reviewed journal Clinical Infectious Diseases.
Validation in cattle
PBD Biotech is currently verifying Actiphage test for the detection of Mycobacterium bovis (bovine TB) and M. avium subsp paratuberculosis (MAP, also known as Johne’s disease) in cattle blood.
Certification of Actiphage by the World Organisation for Animal Health (OIE) as an internationally recognised diagnostic for bTB is PBD Biotech’s primary focus for animal health.
In addition to humans and livestock, Actiphage has also been used as a research tool to identify mycobacteria diseases in over 20 other species including: bison, deer, camelids and lions.